Thirty-day safety and efficacy of prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for non-urgent indications and anticoagulated with bivalirudin

IJC Metabolic and Endocrine

Volumn 2, Issue , 2014, Pages 26-29

  Benjamin, Mina M ^a   McMaster, Kelly S ^a,b   Stoler, Robert C ^a,b,c   Schussler, Jeffrey M ^a,b,c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Division of Cardiology   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Clopidogrel; Coronary artery disease; Percutaneous coronary intervention; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HIRULOG; PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOPLASTY; ARTICLE; BLEEDING; EVALUATION AND FOLLOW UP; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; Q WAVE; RETROPERITONEAL HEMORRHAGE; STENT THROMBOSIS; THROMBOCYTE COUNT; UNSTABLE ANGINA PECTORIS;

EID: 84895473326     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2014.02.001     Document Type: Article

References (9)

1. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
2. Lincoff A.M., Kleiman N.S., Kereiakes D.J., et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004, 292:696-703.
3. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203-2216.
4. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358:2218-2230.
5. Laynez A., Sardi G., Torguson R., et al. Safety and efficacy of prasugrel use in patients undergoing percutaneous coronary intervention and anticoagulated with bivalirudin. Am J Cardiol 2013 Feb 15, 111(4):516-520.
6. Rao S.V., O'Grady K., Pieper K.S., et al. A comparison of the clinical impact of bleeding measured by 2 different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006, 47:809-816.
7. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007, 116:2923-2932.
8. Mahoney E.M., Wang K., Arnold S.V., Proskorovsky I., Wiviott S., Antman E., Braunwald E., Cohen D.J. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010, 121(1):71-79.
9. Benjamin M.M., Filardo G., Donsky M.S., Schussler J.M. A pilot study of prasugrel followed by post-procedural maintenance with clopidogrel in patients receiving percutaneous coronary intervention. J Interv Cardiol 2013 Feb, 26(1):38-42.